Skip to Main Content

Author Details

Mohammad Athar
University of Alabama at Birmingham
1987
332
57
Jake Y. Chen (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
36828949Enhanced Transdermal Delivery of N-Acetylcysteine and 4-Phenylbutyric Acid for Potential Use as Antidotes to Lewisite.AAPS PharmSciTech2023
35362847Mechanistic understanding of the toxic effects of arsenic and warfare arsenicals on human health and environment.Cell Biol Toxicol2023
37469559Protein structural insights into a rare PCSK9 gain-of-function variant (R496W) causing familial hypercholesterolemia in a Saudi family: whole exome sequencing and computational analysis.Front Physiol2023
36828949Enhanced Transdermal Delivery of N-Acetylcysteine and 4-Phenylbutyric Acid for Potential Use as Antidotes to Lewisite.AAPS PharmSciTech2023
37332597Mechanism underlying follicular hyperproliferation and oncogenesis in hidradenitis suppurativa.iScience2023
36873547Anti-<i>E. coli</i> Immunoglobulin Yolk (IgY): Reduction of pathogen receptors and inflammation factors could be caused by decrease in <i>E. coli</i> load.Heliyon2023
37248290Mass cytometry uncovers a distinct peripheral immune profile and upregulated CD38 expression in patients with hidradenitis suppurativa.Cell Mol Immunol2023
36539053Retinal injury mouse model and pathophysiological assessment of the effect of arsenical vesicants.Exp Eye Res2023
37166470Pulmonary pathogenesis in a murine model of inhaled arsenical exposure.Arch Toxicol2023
36851040Substantial Changes in Selected Volatile Organic Compounds (VOCs) and Associations with Health Risk Assessments in Industrial Areas during the COVID-19 Pandemic.Toxics2023
37522678Role of single nucleotide polymorphism rs2383206 on coronary artery disease risk among Saudi Population: a case-control study.Eur Rev Med Pharmacol Sci2023
37511917Novel LDLR Variant in Familial Hypercholesterolemia: NGS-Based Identification, In Silico Characterization, and Pharmacogenetic Insights.Life (Basel)2023
37484345Corrigendum to "Anti- <i>E. coli</i> immunoglobulin yolk (IgY): Reduction of pathogen receptors and inflammation factors could be caused by decrease in <i>E. coli</i> load" [Heliyon 9(3) (February 21, 2023) e13876]&gt;.Heliyon2023
37423342SARS-CoV-2 vaccine breakthrough infections (VBI) by Omicron variant (B.1.1.529) and consequences in structural and functional impact.Cell Signal2023
36780670Cutaneous Exposure to Arsenicals Is Associated with Development of Constrictive Bronchiolitis in Mice.Am J Respir Cell Mol Biol2023
37522678Role of single nucleotide polymorphism rs2383206 on coronary artery disease risk among Saudi Population: a case-control study.Eur Rev Med Pharmacol Sci2023
37484345Corrigendum to "Anti- <i>E. coli</i> immunoglobulin yolk (IgY): Reduction of pathogen receptors and inflammation factors could be caused by decrease in <i>E. coli</i> load" [Heliyon 9(3) (February 21, 2023) e13876]&gt;.Heliyon2023
37511917Novel LDLR Variant in Familial Hypercholesterolemia: NGS-Based Identification, In Silico Characterization, and Pharmacogenetic Insights.Life (Basel)2023
35362847Mechanistic understanding of the toxic effects of arsenic and warfare arsenicals on human health and environment.Cell Biol Toxicol2023
37423342SARS-CoV-2 vaccine breakthrough infections (VBI) by Omicron variant (B.1.1.529) and consequences in structural and functional impact.Cell Signal2023
37248290Mass cytometry uncovers a distinct peripheral immune profile and upregulated CD38 expression in patients with hidradenitis suppurativa.Cell Mol Immunol2023
37469559Protein structural insights into a rare PCSK9 gain-of-function variant (R496W) causing familial hypercholesterolemia in a Saudi family: whole exome sequencing and computational analysis.Front Physiol2023
37166470Pulmonary pathogenesis in a murine model of inhaled arsenical exposure.Arch Toxicol2023
37332597Mechanism underlying follicular hyperproliferation and oncogenesis in hidradenitis suppurativa.iScience2023
36851040Substantial Changes in Selected Volatile Organic Compounds (VOCs) and Associations with Health Risk Assessments in Industrial Areas during the COVID-19 Pandemic.Toxics2023
36780670Cutaneous Exposure to Arsenicals Is Associated with Development of Constrictive Bronchiolitis in Mice.Am J Respir Cell Mol Biol2023
36873547Anti-<i>E. coli</i> Immunoglobulin Yolk (IgY): Reduction of pathogen receptors and inflammation factors could be caused by decrease in <i>E. coli</i> load.Heliyon2023
36539053Retinal injury mouse model and pathophysiological assessment of the effect of arsenical vesicants.Exp Eye Res2023
33242578Epigenetic regulation in the pathogenesis of non-melanoma skin cancer.Semin Cancer Biol2022
35775377CYP11A1â¿¿derived vitamin D hydroxyderivatives as candidates for therapy of basal and squamous cell carcinomas.Int J Oncol2022
36170149Development and Evaluation of a Topical Foam Formulation for Decontamination of Warfare Agents.Mol Pharm2022
35508247Recent advancements, trends, fundamental challenges and opportunities in spray deposited cellulose nanofibril films for packaging applications.Sci Total Environ2022
35678766Role of hair follicles in the pathogenesis of arsenical-induced cutaneous damage.Ann N Y Acad Sci2022
35472745Combined inhibition of BET bromodomain and mTORC1/2 provides therapeutic advantage for rhabdomyosarcoma by switching cell death mechanism.Mol Carcinog2022
36318154Conformationally Defined Rexinoids for the Prevention of Inflammation and Nonmelanoma Skin Cancers.J Med Chem2022
36317800Neuroendocrine signaling in the skin with a special focus on the epidermal neuropeptides.Am J Physiol Cell Physiol2022
36189285Combinatorial suicide gene strategies for the safety of cell therapies.Front Immunol2022
35398795A mechanistic approach for toxicity and risk assessment of heavy metals, hydroquinone and microorganisms in cosmetic creams.J Hazard Mater2022
33242578Epigenetic regulation in the pathogenesis of non-melanoma skin cancer.Semin Cancer Biol2022
35318165Development of BRD4 inhibitors as anti-inflammatory agents and antidotes for arsenicals.Bioorg Med Chem Lett2022
35301634Ex Vivo Culture Models of Hidradenitis Suppurativa for Defining Molecular Pathogenesis and Treatment Efficacy of Novel Drugs.Inflammation2022
35046899A Novel Tree Shrew Model of Diabetic Retinopathy.Front Endocrinol (Lausanne)2022
35249492Identification of Novel and Known LDLR Variants Triggering Severe Familial Hypercholesterolemia in Saudi Families.Curr Vasc Pharmacol2022
35027465The Challenge of Melanoma Chemoprevention.Cancer Prev Res (Phila)2022
35200041Fibrinogen mediates cadmium-induced macrophage activation and serves as a predictor of cadmium exposure in chronic obstructive pulmonary disease.Am J Physiol Lung Cell Mol Physiol2022
35131152Advances in molecular pathogenesis of hidradenitis suppurativa: Dysregulated keratins and ECM signaling.Semin Cell Dev Biol2022
35078134UALCAN: An update to the integrated cancer data analysis platform.Neoplasia2022
35082795Dynamic Regulation of the Nexus Between Stress Granules, Roquin, and Regnase-1 Underlies the Molecular Pathogenesis of Warfare Vesicants.Front Immunol2022
35775377CYP11A1â¿¿derived vitamin D hydroxyderivatives as candidates for therapy of basal and squamous cell carcinomas.Int J Oncol2022
35678766Role of hair follicles in the pathogenesis of arsenical-induced cutaneous damage.Ann N Y Acad Sci2022
  • 1 - 50 of 664

Recommended Authors

Shandong Jianzhu University
Career Start Year 2014
Number of shared co-authors 0
Faculty of Pharmacy, University of Seville
Career Start Year 2010
Number of shared co-authors 0
Roswell Park Comprehensive Cancer Center
Career Start Year 2009
Number of shared co-authors 0
College of Life Science, China Medical University Taichung 406040
Career Start Year 2002
Number of shared co-authors 0
Genomic Medicine Institute, Medical Research Center, Seoul National University
Career Start Year 2000
Number of shared co-authors 0
Chalmers University of Technology
Career Start Year 2000
Number of shared co-authors 0
Moffitt Cancer Center and Research Institute
Career Start Year 1999
Number of shared co-authors 0
Kaohsiung Medical University
Career Start Year 1998
Number of shared co-authors 0
Department of Pharmacy Practice, Manipal College of Pharmaceutical Sciences
Career Start Year 1998
Number of shared co-authors 0
Basic Medical College, Qingdao University
Career Start Year 1998
Number of shared co-authors 0
Soonchunhyang University Hospital Seoul
Career Start Year 1995
Number of shared co-authors 0
German Cancer Research Center (DKFZ)
Career Start Year 1993
Number of shared co-authors 0
Visva-Bharati University
Career Start Year 1993
Number of shared co-authors 0
Emory University
Career Start Year 1992
Number of shared co-authors 0
Xijing Hospital, The Fourth Military Medical University
Career Start Year 1992
Number of shared co-authors 1
International University of Health and Welfare (IUHV Hospital)
Career Start Year 1989
Number of shared co-authors 1
Asan Medical Center, University of Ulsan College of Medicine
Career Start Year 1988
Number of shared co-authors 0
National Institute of Environmental Health Sciences
Career Start Year 1988
Number of shared co-authors 1
University of Texas M.D. Anderson Cancer Center
Career Start Year 1987
Number of shared co-authors 0
University of Iowa
Career Start Year 1986
Number of shared co-authors 0
Maastricht University
Career Start Year 1981
Number of shared co-authors 1
Cancer Center, Sanford Burnham Prebys Medical Discovery Institute
Career Start Year 1981
Number of shared co-authors 0
Oregon Health & Science University
Career Start Year 1980
Number of shared co-authors 0
Battelle Memorial Institute
Career Start Year 1978
Number of shared co-authors 0
Chulabhorn Research Institute
Career Start Year 1978
Number of shared co-authors 0
Moores Cancer Center, university of california san diego
Career Start Year 1977
Number of shared co-authors 0
Emory University School of Medicine
Career Start Year 1977
Number of shared co-authors 0
Center for Research and Advanced Studies of the National Polytechnic Institute
Career Start Year 1976
Number of shared co-authors 0
PHusis Therapeutics Inc.
Career Start Year 1970
Number of shared co-authors 0
National Cancer Institute
Career Start Year 1945
Number of shared co-authors 0

Collaborators

University of Alabama
Co-authored papers 67
Co-authored papers 53
Co-authored papers 35
Co-authored papers 29
Co-authored papers 29
Co-authored papers 21
Co-authored papers 20
University of Massachusetts Medical School
Co-authored papers 18
Co-authored papers 18
Co-authored papers 17
Co-authored papers 11
Co-authored papers 10
Co-authored papers 10
Co-authored papers 10
Co-authored papers 9
Co-authored papers 8
Co-authored papers 8
Co-authored papers 7
University of Alabama at Birmingham
Co-authored papers 7
Co-authored papers 7
Perelman School of Medicine, University of Pennsylvania
Co-authored papers 6
Heersink School of Medicine, University of Alabama at Birmingham
Co-authored papers 5
Co-authored papers 5
University of Alabama at Birmingham
Co-authored papers 5
Co-authored papers 5
MirX Pharmaceuticals
Co-authored papers 5
University of Alabama at Birmingham
Co-authored papers 4
University of Alabama at Birmingham
Co-authored papers 4
Institute of Cancer Genetics, Columbia University Irving Medical Center
Co-authored papers 4
University of Alabama at Birmingham
Co-authored papers 4